To prepare imsEVs for immunotherapy of GBM, we first set out to attach both GBM-targeting (anti-CD71) and immunotherapy (anti-PD-L1) antibodies to the surfaces of imsEVs to enable their specific targeting of GBM for immunotherapeutic effects. Here, TFRC is linked to glioblastoma.